Showing results (541-550 of 610) with videos related to
Sort By:
Pageof 61
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerAlice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.Nature Communications|August 11, 2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsRyohei Katayama, Bo Gong, Noriko Togashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentSaiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.Medchemcomm|July 24, 2018
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyraseKatherine A Hurley, Thiago M A Santos, Molly R Fensterwald, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.Pageof 61